|
KMID : 0360220080490121935
|
|
Journal of the Korean Ophthalmological Society
2008 Volume.49 No. 12 p.1935 ~ p.1940
|
|
|
Long-term Effect of Intravitreal Bevacizumab for CNV Secondary to Age-Related Macular Degeneration
|
|
Kim Yong-Hwan
Yu Seung-Young
Hyung Woo Kwak
Kim Eung-Suk
|
|
|
Abstract
|
|
|
Purpose: To investigate the long-term therapeutic effect and safety of repeated intravitreal bevacizumab injections for managing choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Methods: Clinical data of 14 eyes of 14 patients who were treated with repeated (3 times or more) intravitreal bevacizumab injections for secondary to AMD and followed up for 12 months were collected. Patients were treated with 1.25 mg of intravitreal bevacizumab. Bevacizumab was injected at 6-week intervals. Reinjection was performed with the same method according to the physician’s decision.
Results: Mean visual acuity change increased by 4.0 lines from 1.13±0.47 to 0.73±0.44 (LogMAR). Mean central retinal thickness change decreased by 114.8 μm from 240.3±123.8 μm to 125.5±39.4 μm. Visual acuity improved statistically significantly at 12 weeks after first intravitreal bevacizumab injections and was maintained for 12 months. Central retinal thickness decreased statistically significantly at 6 weeks after the first intravitreal bevacizumab injection and was maintained for 12 months. During the 12 months of 4 intravitreal bevacizumab injections, mean visual acuity change increased by 4.0 lines at 12 months and 4.4 lines at 7 months.
Conclusions: Intravitreal bevacizumab injection causes a significant decrease in central retinal thickness and improvement in visual acuity in eyes with CNV due to AMD for 12 months.
|
|
|
KEYWORD
|
|
|
Age-related macular degeneration, Avastin, Bevacizumab, Choroidal neovascularization, Optical coherence tomography
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|